Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/ G724S Mutation

被引：0
|
作者：
Lyu, X. [1 ]
Jiao, T. [1 ]
Yang, S. [1 ]
Yang, S. [1 ]
机构：
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
lung adenocarcinoma; targeted therapy; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-08
引用
收藏
页码：S643 / S643
页数：1
相关论文
共 50 条
  • [1] Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
    Zhang, Xiaoying
    GLOBAL MEDICAL GENETICS, 2021, 08 (04): : 133 - 134
  • [2] Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
    Oztan, A.
    Fischer, S.
    Schrock, A. B.
    Erlich, R. L.
    Lovly, C. M.
    Stephens, P. J.
    Ross, J. S.
    Miller, V.
    Ali, S. M.
    Ou, S. -H. I.
    Raez, L. E.
    LUNG CANCER, 2017, 111 : 84 - 87
  • [3] Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M
    Senoo, Satoru
    Ohashi, Kadoaki
    Nishii, Kazuya
    Hara, Naofumi
    Kano, Hirohisa
    Ninomiya, Kiichiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E140 - E142
  • [4] Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
    Joshi, Asim
    Butle, Ashwin
    Hait, Supriya
    Mishra, Rohit
    Trivedi, Vaishakhi
    Thorat, Rahul
    Choughule, Anuradha
    Noronha, Vanita
    Prabhash, Kumar
    Dutt, Amit
    TRANSLATIONAL ONCOLOGY, 2022, 22
  • [5] Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
    Wang, Yanyan
    Jiang, Chenchen
    Tang, Mingyue
    Li, Huiyuan
    Zhao, Cancan
    Zhao, Menglin
    Zhang, Yue
    Li, Xinwei
    Mi, Jiaqi
    Shen, Honghong
    Wang, Zishu
    Su, Fang
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2023, 13 (08) : 5362 - 5368
  • [6] Effects of vandetanib on lung adenocarcinoma cells harboring an EGFR T790M mutation in vivo
    Ichihara, Eiki
    Ohashi, Kadoaki
    Takigawa, Nagio
    Osawa, Masahiro
    Takeda, Hiromasa
    Ochi, Nobuaki
    Harada, Daijiro
    Yasugi, Masayuki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2009, 69
  • [7] Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
    Sakai, Hitomi
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Hasegawa, Yoshikazu
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    ESMO OPEN, 2017, 2
  • [8] Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
    Maekinen, Netta
    Zhou, Meng
    Bemus, Meredith
    Nevin, Julius
    Nag, Anwesha
    Chen, Ruthia
    Colson, Yolonda L.
    Thorner, Aaron R.
    Oxnard, Geoffrey R.
    Meyerson, Matthew
    Sholl, Lynette M.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (04):
  • [9] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
    Zhao, S.
    Jiang, T.
    Li, X.
    Zhao, C.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
  • [10] Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
    Zhang, Yan
    He, Bixiu
    Zhou, Dongbo
    Li, Min
    Hu, Chengping
    ONCOTARGETS AND THERAPY, 2019, 12 : 51 - 56
12345